Identifying novel inhibitors targeting Exportin-1 for the potential treatment of COVID-19

Arch Microbiol. 2024 Jan 19;206(2):69. doi: 10.1007/s00203-023-03761-z.

Abstract

The nuclear export protein 1 (XPO1) mediates the nucleocytoplasmic transport of proteins and ribonucleic acids (RNAs) and plays a prominent role in maintaining cellular homeostasis. XPO1 has emerged as a promising therapeutic approach to interfere with the lifecycle of many viruses. In our earlier study, we proved the inhibition of XPO1 as a therapeutic strategy for managing SARS-COV-2 and its variants. In this study, we have utilized pharmacophore-assisted computational methods to identify prominent XPO1 inhibitors. After several layers of screening, a few molecules were shortlisted for further experimental validation on the in vitro SARS-CoV-2 cell infection model. It was observed that these compounds reduced spike positivity, suggesting inhibition of SARS-COV-2 infection. The outcome of this study could be considered further for developing novel antiviral therapeutic strategies against SARS-CoV-2.

Keywords: Docking; Machine learning; Molecular dynamics; SARS-CoV-2; XPO1.

MeSH terms

  • Active Transport, Cell Nucleus
  • COVID-19*
  • Exportin 1 Protein* / antagonists & inhibitors
  • Humans
  • SARS-CoV-2

Substances

  • XPO1 protein, human
  • Exportin 1 Protein